VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | CONKO-007: chemoradiotherapy increases rates of R0 resection in locally advanced pancreatic cancer

Rainer Fietkau, MD, PhD, University Hospital Erlangen, Erlangen, Germany, discusses the Phase III CONKO-007 trial (NCT01827553) trial designed to compare chemoradiotherapy (CRT) versus chemotherapy for patients with unresectable, locally advanced pancreatic cancer who had already received induction chemotherapy. No significant differences were observed in progression-free survival (PFS) or overall-survival (OS) between those receiving CRT and chemotherapy. However, in patients who underwent resection, R0 resections were significantly higher for patients receiving CRT than chemotherapy alone. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter